LAI Consortium Agreement Signed by All Partners

Twelve medical centers from Europe, the U.S., and Australia formalize collaboration to fast-forward the use of AI for liver lesion diagnosis.

The Liver Artificial Intelligence (LAI) consortium has officially finalized and signed its consortium agreement, marking a major step forward in its mission to improve MRI-based diagnosis of liver lesions with AI.

The LAI Consortium brings together leading hospitals and research centers across three continents to create a benchmark MRI dataset of over 3,000 patients with pathologically confirmed liver lesions. This dataset will support the development and validation of AI tools to assist in the diagnosis of solid-appearing liver lesions on MRI.

By partnering with diverse institutions and including a wide range of patient profiles, liver diseases, and imaging equipment, the consortium aims to ensure that the resulting AI tools are robust and globally applicable.

Our current partners are:

• Erasmus University Medical Center Rotterdam, The Netherlands
• Academisch Ziekenhuis Maastricht, The Netherlands
• University Medical Center Utrecht, The Netherlands
• University Medical Center Groningen, The Netherlands
• Stichting Amsterdam UMC, The Netherlands
• Assistance Publique – Hôpitaux de Paris, France
• Università Di Pisa, Italy
• Università Degli Studi Di Palermo, Italy
• Institute Jules Bordet, Belgium
• Medical University of Gdansk, Poland
• Icahn School of Medicine at Mount Sinai, United States of America
• Austin Health, Australia

If you are interested in joining our effort to improve liver lesion diagnosis, please contact us at lai.info@erasmusmc.nl.